Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sciformix to Reveal Strategic Model for Talent Acquisition at the DIA 50th Annual Meeting

Published: Thursday, May 22, 2014
Last Updated: Thursday, May 22, 2014
Bookmark and Share
New career strategy aims to address talent acquisition and retention requirements for capacity expansion.

Sciformix Corporation will unveil a new strategic model for talent acquisition and retention at the DIA 50th Annual Meeting, San Diego, California, which will take place 15th to 19th June.

The new model will demonstrate the ability to cater for the increasing demand for talent in the CRO industry, enabling capacity expansion without compromising productivity and the quality of deliverables.

The talent pool for the CRO industry is currently at a critical level, with an ever increasing demand for trained candidates, especially in highly skilled roles.

The demand-supply skew has stretched the limit of current hiring practices aimed at external sourcing of experienced talent. The problem is more acute for companies such as Sciformix, that work in areas of high science and high domain where lateral hiring isn’t the solution.

Sciformix has implemented a novel model of systematized training by developing a structured curriculum both for entry level and experienced candidates. By focusing on in-house professional development, the program will provide not only a stream of trained resources, but also make experienced resources productive on complex assignments they don’t have prior experience on.

In a presentation, to take place at DIA 50th Annual Meeting on 19th June, Dr. Samyuktha Ajay, Practice Head for Clinical Research and Post-Approval Support Services at Sciformix, will outline this new strategic initiative and share the experience and benefits of the program.

Dr. Ajay said: “According to various market research reports, the CRO industry is expected to grow to $32.7 billion by next year, to over $65.0 billion by 2021, and has created an increased demand for a rich talent pool of medical, paramedical and science graduates to supply capacity expansion. CROs and their service providers are creating new positions and promoting internal employees which is driving significant movement amongst companies and, thus, creating further resource crunch. Despite candidates being readily available, finding the right match requires the adoption of a multi-dimensional strategy. Through sharing our extensive experience of in-house training at all levels, we aim to project a program which offers a structured career path and excellent retention strategy.”

The DIA 2014 50th annual meeting is the largest multidisciplinary event that brings together the community of life sciences professionals at all levels and across all disciplines involved in the discovery, development and life cycle management of medical products and therapies to patients.

DIA will provide a platform to raise the level of discussion to facilitate innovation that will change the future of health care and it will provide coverage of the full development and life cycle management of process for health care products.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Sciformix Rated Among the ‘Top 20 Most Promising Pharma and Life Sciences Solution Providers’
Sciformix Corporation has been recognized as one of the Top 20 Most Promising “Pharma & Life Sciences Solution Providers - 2016” in a recent feature by Silicon India.
Monday, April 25, 2016
Sciformix Corporation CSO Honoured in PharmaVOICE 100
Dr. Chitra Lele is recognized for pioneering work in service provision across global markets.
Friday, August 01, 2014
Sciformix Awarded Pharmaceutical KPO Entrepreneurial Company of the Year
Company has received this prestigious award from Frost & Sullivan.
Thursday, July 18, 2013
Scientific News
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Combination Therapy Improved Chemoresistance in Ovarian Cancer
The study demonstrates how an existing class of targeted therapies could be used to potentiate the tumor suppression induced by cisplatin.
Gene Therapy for Blistering Skin Disease Shows Promise
Grafting genetically altered skin onto patients’ chronic wounds marks the first time skin-based gene therapy has been demonstrated to be safe and effective in humans.
Alzheimer’s Treatment Moves a Step Closer
Merck scientists have reported the discovery of verubecestat, a structurally unique, orally bioavailable small molecule that has been shown to target the most visible sign of the disease in the brain.
Lynparza Phase III Progression-Free Survival Benefit
AstraZeneca announces results from Phase III SOLO-2 trial designed to determine the efficacy of Lynparza as a monotherapy for ovarian cancer.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!